Valoración de efectos ecotoxicológicos de oxitetraciclina en organismos terrestres y acuáticos mediante el empleo de sistemas multi-especie en suelo (MS3)

La importancia del suelo radica en las numerosas funciones que desempeña, tanto ambientales como socio-económicas y culturales. El suelo es el fundamento del sistema alimentario, la base de la agricultura y el medio en el que crecen casi todas las plantas destinadas a la producción de alimento, es un recurso prácticamente no renovable y es un medio vivo con gran biodiversidad cuya actividad biológica contribuye a determinar la estructura y fertilidad, y resulta ser fundamental para que este pueda realizar algunas de sus funciones. La incorporación al suelo de agentes contaminantes químicos o abióticos por encima de su capacidad de amortiguación supone su contaminación y en consecuencia la contaminación de las aguas subterráneas y/o superficiales. La presencia en el suelo de elementos tóxicos puede suponer un riesgo para la salud humana y/o los ecosistemas La presencia de medicamentos en el medio ambiente se ha convertido en un tema muy actual de investigación. Las técnicas cromatográficas actuales permiten alcanzar límites de detección analítica, en rangos comprendidos entre ng/l a μg/l, lo que ha permitido cuantificar un gran número de principios activos de uso farmacológico y excipientes en el medio ambiente, obligando a la comunidad científica a considerar este tipo de contaminación como un potencial problema que merece su atención. Hoy en día, se conoce, su amplia difusión a bajas concentraciones principalmente en el medio ambiente acuático. Tales concentraciones se han detectado en los compartimentos acuáticos, tales como los influentes y efluentes de plantas depuradoras de aguas residuales (EDAR), las aguas superficiales (ríos, lagos, arroyos, y estuarios, entre otros), el agua de mar, las aguas subterráneas y el agua potable..

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

Composición química y digestibilidad de cuatro leguminosas tropicales mexicanas

In Mexico, the nutritional properties of tropical legumes are not widely known. Therefore, the objective of the present study was to evaluate the nutritional value of Arachis pintoi, Clitoria ternatea, Macroptilium atropurpureumand Stylosanthes guianensis. Crude protein (CP), crude fiber (CF), ether extract (EE), ash (ASH), acid detergent fiber (ADF), neutral detergent fiber (NDF), crude lignin (CL), in vitrodigestibility of dry matter (IVDDM) and in situdigestibility DM (DISDM). The samples were collected in the experimental plots of the National Institute of Forest, Agricultural and Livestock Research, Veracruz state, Mexico. The evaluations were carried out in the facilities of the Zootechnics Department, Autonomous University Chapingo, State ofMexico, Mexico. Each species was evaluated, with three repetitions and each repetition was considered the experimental unit, resulting in twelve observations per variable. The means were separated using the Tukey test (p< 0.05). Arachis pintoishowed the highest percentages of CP (25.2%), ASH (9.0%), IVDDM(83.2%) and ISDDM(88.0%), and the lowest values of NDF (32.8%), ADF (26.9%) and CL (5.5%). Macroptilium atropurpureum showed the lowest percentages of CP, IVDDM, IVDDM and ASH (6.4%), and the highest values of NDF (50.9%), ADF (37.6%) and CL (11.8%). The other legumes showed intermediate or low values of all variables. Therefore, based on chemical composition and, in vitroand in situ dry matter digestibility, Arachis pintoiwas the species with the best nutritional valueEn México, las propiedades nutricionales de las leguminosas tropicales no se conocen ampliamente. Por tanto, el objetivo del presente estudio fue evaluar el valor nutricional de Arachis pintoi, Clitoria ternatea, Macroptilium atropurpureum y Stylosanthes guianensis. Se evaluaron, proteína cruda (PC), fibra cruda (FC), extracto etéreo (EE), cenizas (CEN), fibra detergente ácido (FDA), fibra detergente neutro (FDN), lignina cruda (LC), digestibilidad in vitro de la materia seca (DIVMS) y digestibilidad in situ de la MS (DISMS). Las muestras se colectaron en las parcelas experimentales del INIFAP, estado de Veracruz, México. Las evaluaciones se realizaron en el Departamento de Zootecnia, Universidad Autónoma Chapingo. Cada especie se evaluó, con tres repeticiones y cada repetición se consideró la unidad experimental, resultando doce observaciones por variable. Las medias se separaron mediante la prueba de Tukey (p< 0.05). Arachis pintoi mostró los porcentajes más altos de PC (25.2%), CEN (9%), DIVMS (83.2%) y DISMS (88.0%) y los valores más bajos de FDN (32.8%), FDA (26.9%) y LC (5.5%). Macroptilium atropurpureum mostró los porcentajes más bajos de PC, DIVMS, DISMS y CEN (6.4%) y los valores altos de FDN (50.9%), FDA (37.6%) y LC (11.8%). Las otras leguminosas mostraron valores intermedios o bajos de todas las variables. Por tanto, con base en la composición química y la digestibilidad in vitro e in situ de la materia seca, Arachis pintoi fue la especie con el mejor valor nutricional

Clinical manifestations of intermediate allele carriers in Huntington disease

Objective: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry. Methods: We assessed a cohort of participants at risk with <36 CAG repeats of the huntingtin (HTT) gene. Outcome measures were the Unified Huntington's Disease Rating Scale (UHDRS) motor, cognitive, and behavior domains, Total Functional Capacity (TFC), and quality of life (Short Form-36 [SF-36]). This cohort was subdivided into IA carriers (27-35 CAG) and controls (<27 CAG) and younger vs older participants. IA carriers and controls were compared for sociodemographic, environmental, and outcome measures. We used regression analysis to estimate the association of age and CAG repeats on the UHDRS scores. Results: Of 12,190 participants, 657 (5.38%) with <36 CAG repeats were identified: 76 IA carriers (11.56%) and 581 controls (88.44%). After correcting for multiple comparisons, at baseline, we found no significant differences between IA carriers and controls for total UHDRS motor, SF-36, behavioral, cognitive, or TFC scores. However, older participants with IAs had higher chorea scores compared to controls (p 0.001). Linear regression analysis showed that aging was the most contributing factor to increased UHDRS motor scores (p 0.002). On the other hand, 1-year follow-up data analysis showed IA carriers had greater cognitive decline compared to controls (p 0.002). Conclusions: Although aging worsened the UHDRS scores independently of the genetic status, IAs might confer a late-onset abnormal motor and cognitive phenotype. These results might have important implications for genetic counseling. ClinicalTrials.gov identifier: NCT01590589

Optimization of adsorptive removal of α-toluic acid by CaO2 nanoparticles using response surface methodology

The present work addresses the optimization of process parameters for adsorptive removal of α-toluic acid by calcium peroxide (CaO2) nanoparticles using response surface methodology (RSM). CaO2 nanoparticles were synthesized by chemical precipitation method and confirmed by Transmission electron microscopy (TEM) and high-resolution TEM (HRTEM) analysis which shows the CaO2 nanoparticles size range of 5–15 nm. A series of batch adsorption experiments were performed using CaO2 nanoparticles to remove α-toluic acid from the aqueous solution. Further, an experimental based central composite design (CCD) was developed to study the interactive effect of CaO2 adsorbent dosage, initial concentration of α-toluic acid, and contact time on α-toluic acid removal efficiency (response) and optimization of the process. Analysis of variance (ANOVA) was performed to determine the significance of the individual and the interactive effects of variables on the response. The model predicted response showed a good agreement with the experimental response, and the coefficient of determination, (R2) was 0.92. Among the variables, the interactive effect of adsorbent dosage and the initial α-toluic acid concentration was found to have more influence on the response than the contact time. Numerical optimization of process by RSM showed the optimal adsorbent dosage, initial concentration of α-toluic acid, and contact time as 0.03 g, 7.06 g/L, and 34 min respectively. The predicted removal efficiency was 99.50%. The experiments performed under these conditions showed α-toluic acid removal efficiency up to 98.05%, which confirmed the adequacy of the model prediction

Clinical and genetic characteristics of late-onset Huntington's disease

Background: The frequency of late-onset Huntington's disease (&gt;59 years) is assumed to be low and the clinical course milder. However, previous literature on late-onset disease is scarce and inconclusive. Objective: Our aim is to study clinical characteristics of late-onset compared to common-onset HD patients in a large cohort of HD patients from the Registry database. Methods: Participants with late- and common-onset (30–50 years)were compared for first clinical symptoms, disease progression, CAG repeat size and family history. Participants with a missing CAG repeat size, a repeat size of ≤35 or a UHDRS motor score of ≤5 were excluded. Results: Of 6007 eligible participants, 687 had late-onset (11.4%) and 3216 (53.5%) common-onset HD. Late-onset (n = 577) had significantly more gait and balance problems as first symptom compared to common-onset (n = 2408) (P &lt;.001). Overall motor and cognitive performance (P &lt;.001) were worse, however only disease motor progression was slower (coefficient, −0.58; SE 0.16; P &lt;.001) compared to the common-onset group. Repeat size was significantly lower in the late-onset (n = 40.8; SD 1.6) compared to common-onset (n = 44.4; SD 2.8) (P &lt;.001). Fewer late-onset patients (n = 451) had a positive family history compared to common-onset (n = 2940) (P &lt;.001). Conclusions: Late-onset patients present more frequently with gait and balance problems as first symptom, and disease progression is not milder compared to common-onset HD patients apart from motor progression. The family history is likely to be negative, which might make diagnosing HD more difficult in this population. However, the balance and gait problems might be helpful in diagnosing HD in elderly patients